Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose-lowering agents. RESEARCH DESIGN AND METHODS: After a 6-week run-in when iGlar was introduced and/or further titrated, and oral antidiabetic drugs other than metformin were stopped, 736 basal insulin-treated patients (mean diabetes duration 12 years, BMI 31 kg/m2) were randomized 1:1 to open-label, once-daily iGlarLixi or iGlar, both titrated to fasting plasma glucose <100 mg/dL (<5.6 mmol/L) up to a maximum dose of 60 units/day. The primary outcome was change in HbA1c levels at 30 weeks. RESULTS: HbA1c decreased from 8.5% (69 mmol/mol) to 8.1% (65 mmol/mol) during the run-in period. After randomization, iGlarLixi showed greater reductions in HbA1c from baseline compared with iGlar (–1.1% vs. –0.6%, P < 0.0001), reaching a mean final HbA1c of 6.9% (52 mmol/mol) compared with 7.5% (58 mmol/mol) for iGlar. HbA1c <7.0% (53 mmol/mol) was achieved in 55% of iGlarLixi patients compared with 30% on iGlar. Mean body weight decreased by 0.7 kg with iGlarLixi and increased by 0.7 kg with iGlar (1.4 kg difference, P < 0.0001). Documented symptomatic hypoglycemia (≤70 mg/dL) was comparable between groups. Mild gastrointestinal adverse effects were very low but more frequent with iGlarLixi. CONCLUSIONS: Compared with iGlar, a substantially higher proportion of iGlarLixi-treated patients achieved glycemic targets with a beneficial effect on body weight, no additional risk of hypoglycemia, and low levels of gastrointestinal adverse effects in inadequately controlled, basal insulin-treated, long-standing type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In studies of people with type 2 diabetes inadequately controlled on basal insulin or GLP-1 RA, switching to a fi xedratio combination of basal insulin and GLP-1 RA demonstrated signi fi cant improvements in blood glucose levels and achievement of glycemic goals with fewer hypoglycemic events than with basal insulin alone (216 -220).”
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“mitigate the weight gain observed with insulin therapy (4,6–9); GLP-1 RAs do, however, present a risk of gastrointestinal adverse events (AEs), leading to frequent discontinuations (10).”
BackgroundSelf-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Basal Insulin Therapy in Type 2 Diabetes
Rosenstock, J., Schwartz, S. L., Clark, C. M., Park, G. D., Donley, D. W., & Edwards, M. B. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.631 · Cited by 478 · cited 1×
“Basal insulin therapy improves fasting plasma glucose (FPG) and nocturnal hypoglycemia (3), whereas GLP-1 RAs, especially the short-acting compounds, have a significant effect on postprandial plasma glucose (PPG) (4–9).”
BackgroundSelf-citationAmerican Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-er09 · Cited by 379
Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288 · cited 1×
“treatment, generally in the 25–30% range (7,9,12).”
Self-citationMeier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Self-citationSeino, Y., Min, K. W., Niemoeller, E., Takami, A., & on behalf of the EFC10887 GETGOAL‐L Asia Study Investigators (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01618.x · Cited by 255
Self-citationRiddle, M. C., Forst, T., Aronson, R., Sauque-Reyna, L., Souhami, E., Silvestre, L., Ping, L., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2462 · Cited by 253
Self-citationLingvay, I., Manghi, F. P., García-Hernández, P., Norwood, P., Lehmann, L., Tarp-Johansen, M. J., Buse, J. B., & for the DUAL V Investigators (2016) · JAMA · doi:10.1001/jama.2016.1252 · Cited by 220 · cited 1×
“combination of insulin degludec and the GLP-1 RA liraglutide (17).”
BackgroundRosenstock, J., Guerci, B., Hanefeld, M., Gentile, S., Aronson, R., Tinahones, F. J., Roy-Duval, C., Souhami, E., Wardecki, M., Ye, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0014 · Cited by 133
Self-citationWhen basal insulin therapy in type 2 diabetes mellitus is not enough—what next?
Raccah, D., Bretzel, R. G., Owens, D., & Riddle, M. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.733 · Cited by 112 · cited 1×
“Recommendations from the American Diabetes Association and the European Association for the Study of Diabetes suggest that if HbA1c targets are not achieved despite the addition of basal insulin in type 2 diabetes (1), treatment should be further advanced to combination injectable therapy with the progressive addition…”
BackgroundTreat-to-target trials: uses, interpretation and review of concepts
Garber, A. J. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12129 · Cited by 94 · cited 1×
“5% was consistent with several trials when the basal insulin is titrated robustly but not enough to reach HbA1c targets (13) because further therapy is needed to address postprandial hyperglycemia.”
Rosenstock, J., Diamant, M., Aroda, V. R., Silvestre, L., Souhami, E., Zhou, T., Perfetti, R., Fonseca, V., & for the LixiLan PoC Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0046 · Cited by 86 · cited 1×
“As observed with previous studies (14,15), the Lixi component of iGlarLixi”
ResultSelf-citationLixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis
Charbonnel, B., Bertolini, M., Tinahones, F. J., Domingo, M. P., & Davies, M. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.07.007 · Cited by 48
Raccah, D., Lin, J., Wang, E., Germé, M., Perfetti, R., Bonadonna, R. C., de Pablos-Velasco, P. L., Roussel, R., & Rosenstock, J. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.10.003 · Cited by 33
Self-citation
Research works printed but not linked: 2
- Aroda, 2016, Efficacy and safety of the insulin glargine/lixisenatide fixed-ratio combination vs. insulin glargine in patients with T2DM: the LixiLan-L Trial, Diabetes Care, 65, A62
- Sikirica, 2015, Reasons for discontinuation of GLP-1 receptor antagonists: data from a large cross-sectional survey of physicians and type 2 diabetic patients (Abstract), Diabetes Care, 64, A297
Cited by
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Self-citation
Metadata
- Authors
- Aroda, V. R., Rosenstock, J., Wysham, C., Unger, J., Bellido, D., González-Gálvez, G., Takami, A., Guo, H., Niemoeller, E., Souhami, E., Bergenstal, R. M., & on behalf of the LixiLan-L Trial Investigators
- Affiliations
- MedStar Health Research Institute (US)
- Dallas Diabetes Research Center (US)
- Rockwood Clinic (US)
- Catalina Research Institute (US)
- Universidade da Coruña (ES)
- Universidad de Guadalajara (MX)
- Sanofi (Japan) (JP)
- Biostatistics, BMD Consulting Inc., Somerset, NJ
- Sanofi (Germany) (DE)
- Sanofi (France) (FR)
- Park Nicollet Health Services (US)
- Corresponding author
- Aroda, Vanita R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-09-20
- Volume
- 39
- Issue
- 11
- Pages
- 1972-1980
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2521422828
- Cited by
- 260
- References
- 16
- Citations by year
- 2026: 15 · 2025: 19 · 2024: 24 · 2023: 23 · 2022: 24 · 2021: 27 · 2020: 28 · 2019: 26 · 2018: 46 · 2017: 28
- FWCI
- 33.47
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-06-01)
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin glargine, lixisenatide, basal insulin, type 2 diabetes, glycemic control, HbA1c, metformin, GLP-1 receptor agonists, weight change, hypoglycemia, gastrointestinal adverse effects, inadequate glycemic control
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Insulin Glargine, Aged, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Combinations, Drug Evaluation, Preclinical, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Peptides, Body Mass Index, Treatment Outcome, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.